SGMT:NASDAQ, Sagimet Biosciences Inc.
SGMT stock overview
Sagimet Biosciences Inc. (SGMT:NASDAQ) closed at $9.58 on October 23, 2026,
down 3.72% on the day.
The stock trades 16.3% below its 52-week high of $11.45
and 112.9% above its 52-week low of $4.50.
Over the past year, it gained 4.8%.
Sagimet Biosciences Inc. is part of the Health Care sector.
Key figures
- Price
- $9.58
- Day change
- -3.72%
- Volume
- 694,945
- Average volume
- 1,321,417
- Market cap
- 679M+
- 52-week range
- $4.50 – $11.45
- 50-day average
- $9.95
- 200-day average
- $7.37
Price action over the past year
In 252 trading sessions since October 23, 2025, SGMT closed higher on 117 days (46%).
Its best day was April 27, 2026 (+38.57%) and its worst was September 24, 2026 (-12.57%).
The stock moved 10% or more in a single session 16 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
SGMT news
-
Oct 23, 2026:
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
-
Oct 23, 2026:
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
-
Oct 22, 2026:
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
-
Oct 15, 2026:
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
-
Oct 9, 2026:
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
-
Oct 9, 2026:
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
-
Oct 4, 2026:
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
-
Oct 1, 2026:
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Similar stocks
Find more stocks like SGMT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.